Welcome to our dedicated page for Thermo Fishr Sci SEC filings (Ticker: TMO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Thermo Fisher Scientific Inc. (NYSE: TMO) files a wide range of documents with the U.S. Securities and Exchange Commission, and this page aggregates those SEC filings for investors tracking TMO. The company’s common stock and multiple series of senior notes are listed on the New York Stock Exchange, and its filings describe the terms, rankings and covenants of these securities, as well as material events affecting the business.
Recent Form 8‑K filings illustrate the types of information Thermo Fisher discloses. Several 8‑Ks detail public offerings of senior notes in U.S. dollars and euros, including maturities, interest payment schedules, redemption provisions, change‑of‑control protections and the use of proceeds for general corporate purposes such as acquisitions, debt repayment or refinancing, working capital, capital expenditures or equity repurchases. Other 8‑Ks report the completion of the acquisition of Solventum Corporation’s purification and filtration business and the signing of a definitive agreement to acquire Clario Holdings, Inc.
Thermo Fisher also uses 8‑K filings to communicate quarterly financial results, leadership transitions and organizational changes. For example, filings describe announcements of financial results for specific fiscal quarters, the planned retirement of the Senior Vice President and Chief Financial Officer and the appointment of a successor, and updates to the organizational structure and leadership team, including changes in executive roles.
On Stock Titan’s SEC filings page for TMO, users can access these current reports alongside other registered securities information, and benefit from AI‑powered summaries that explain key terms, highlight significant covenants, and clarify how new debt offerings, acquisitions, leadership changes or other material events may affect Thermo Fisher Scientific’s capital structure and corporate profile.
TMO received a Form 144 notice covering a planned sale of 10,725 shares of common stock through Fidelity Brokerage Services LLC on the NYSE. The filing lists an aggregate market value of 10,725 shares at 6,435,000.00 and notes that 375,708,059 shares of this class were outstanding.
The seller acquired these shares by exercising stock options granted on 02/26/2019 for 8,475 shares and on 09/05/2019 for 2,250 shares, with cash payment made on 11/25/2025. By signing the notice, the seller represents that they do not know of any material adverse information about the issuer’s current or prospective operations that has not been publicly disclosed.
Thermo Fisher Scientific (Finance I) B.V., a Dutch finance subsidiary of Thermo Fisher Scientific Inc., plans to issue euro-denominated floating-rate and fixed-rate senior notes fully and unconditionally guaranteed by Thermo Fisher. The floating notes will pay interest at 3‑month EURIBOR plus a spread with a zero floor, while the fixed notes pay a set annual coupon; both are unsecured senior obligations with no sinking fund.
Thermo Fisher intends to use the euro notes’ net proceeds for general corporate purposes, which may include acquisitions, debt repayment or refinancing, working capital, capital expenditures and share repurchases. The company recently agreed to acquire Clario Holdings, Inc. for $8.875 billion in cash plus up to $525 million of additional and contingent consideration, and in October 2025 issued $2.5 billion of U.S. dollar senior notes for similar corporate uses.
The notes are expected to be listed on the New York Stock Exchange and cleared through Euroclear and Clearstream. Key features include optional redemption for the fixed notes, tax-related redemption rights, a change-of-control repurchase at 101% of principal plus interest, and payment of additional amounts to address specified Dutch and U.S. withholding taxes.
Thermo Fisher Scientific Inc. (TMO) senior vice president and chief financial officer Stephen Williamson reported an insider transaction involving company common stock. On 11/14/2025, he transferred 433 shares of Thermo Fisher common stock in a transaction coded "G," which indicates a gift, at a reported price of $0 per share. Following this transaction, he beneficially owned 31,887.193 shares of common stock directly. He also had 12,674 shares reported as indirectly owned through a SLAT, and he disclaims beneficial ownership of those indirect shares except to the extent of any pecuniary interest.
Thermo Fisher Scientific (TMO) reported an insider transaction by its Sr. VP and Chief HR Officer. On 11/12/2025, the officer sold 1,057.577 shares of common stock at a price of $588.265 per share (Transaction Code S).
Following the sale, the officer’s beneficial ownership is 13,087.227 shares, held directly. No derivative securities were reported in this filing.
Thermo Fisher Scientific (TMO) reported an insider transaction by EVP & COO Michel Lagarde. On 11/13/2025, he exercised 4,638 stock options at $253.99 per share (code M), acquiring common stock, and then sold 4,638 shares at a $594.42 weighted average price (code S). Following these transactions, his directly held common stock was 23,479.909 shares. The sale price reflected multiple trades between $594.36 and $594.88. The option, with a $253.99 exercise price, was originally scheduled to vest in four equal installments on February 26 of 2020–2023 and carried an expiration of 02/26/2026.
TMO: A holder filed a Form 144 notice to sell up to 4,638 shares of common stock through Fidelity Brokerage Services LLC on the NYSE, with an approximate sale date of 11/13/2025.
The filing lists an aggregate market value of 2,756,934.94 for the proposed shares and notes 375,708,059 shares outstanding. The shares to be sold were acquired via an option granted on 02/26/2019 and paid in cash on 11/13/2025.
Thermo Fisher Scientific (TMO) received a Form 144 notice for a proposed sale of up to 1,058 common shares through Fidelity Brokerage Services, with an aggregate market value of $622,135.54. The shares are expected to be sold on the NYSE around 11/12/2025.
The securities were acquired via restricted stock vesting: 1,016 shares on 02/23/2022 and 42 shares on 08/25/2023. A related table shows 10,225 common shares were sold on 11/07/2025 for gross proceeds of $5,844,850.08. Shares outstanding were 375,708,059.
Thermo Fisher Scientific (TMO) reported insider transactions by an Executive Vice President on 11/10/2025 under a Rule 10b5-1 trading plan. The officer exercised 725 options at $253.99 and 2,250 options at $294.02, then sold 725 shares and 2,250 shares at $580.
Following these transactions, the officer beneficially owned 21,152.223 shares of common stock, held directly. The options exercised were previously granted and had vested in four equal annual installments ending in 2023.
Thermo Fisher Scientific (TMO) reported insider transactions by an officer (Sr. VP and Chief HR Officer) on 11/07/2025. The filer sold 1,750 shares of common stock at $571.3977, exercised 8,475 stock options at $253.99, and sold 8,475 shares at $571.6701. Following these trades, the filer directly owned 14,144.804 shares.
The exercised option related to a grant that vested in four equal installments on February 26, 2020, 2021, 2022, and 2023.
Thermo Fisher Scientific (TMO) insider Gianluca Pettiti filed a Form 144 to sell up to 2,975 shares of common stock on or about 11/10/2025 on the NYSE through Fidelity Brokerage Services. The filing lists an aggregate market value of $1,725,500. The shares derive from options granted in 2019 and indicate cash exercise on 11/10/2025. The notice also reports a prior sale of 400 shares on 10/24/2025 for $229,660. Shares outstanding were 375,708,059, a baseline figure.
FAQ
What is the current stock price of Thermo Fishr Sci (TMO)?
What is the market cap of Thermo Fishr Sci (TMO)?
